NCT01515527 2026-02-06
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT00923013 2025-08-08
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00003178 2014-07-25
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
Children's Oncology Group
Phase 2 Completed
NCT00002805 2014-07-24
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Phase 2 Completed
NCT00955916 2014-06-27
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00483067 2012-08-02
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002833 2012-07-30
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00072007 2012-05-15
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
Swiss Cancer Institute
Phase 2 Completed